THTX vs. BTMD, SNDL, CMRX, YMAB, VYGR, LFVN, ITOS, AQST, IMMP, and NGNE
Should you be buying Theratechnologies stock or one of its competitors? The main competitors of Theratechnologies include biote (BTMD), SNDL (SNDL), Chimerix (CMRX), Y-mAbs Therapeutics (YMAB), Voyager Therapeutics (VYGR), LifeVantage (LFVN), iTeos Therapeutics (ITOS), Aquestive Therapeutics (AQST), Immutep (IMMP), and Neurogene (NGNE). These companies are all part of the "pharmaceutical products" industry.
Theratechnologies vs.
Theratechnologies (NASDAQ:THTX) and biote (NASDAQ:BTMD) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, community ranking, risk, analyst recommendations, media sentiment, dividends, profitability, valuation and earnings.
In the previous week, Theratechnologies had 2 more articles in the media than biote. MarketBeat recorded 4 mentions for Theratechnologies and 2 mentions for biote. biote's average media sentiment score of 1.22 beat Theratechnologies' score of 0.96 indicating that biote is being referred to more favorably in the news media.
Theratechnologies has a beta of 1.3, suggesting that its share price is 30% more volatile than the S&P 500. Comparatively, biote has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500.
biote has a consensus target price of $9.11, suggesting a potential upside of 55.20%. Given biote's stronger consensus rating and higher probable upside, analysts clearly believe biote is more favorable than Theratechnologies.
Theratechnologies received 15 more outperform votes than biote when rated by MarketBeat users. However, 100.00% of users gave biote an outperform vote while only 52.73% of users gave Theratechnologies an outperform vote.
biote has a net margin of 5.20% compared to Theratechnologies' net margin of -3.75%. Theratechnologies' return on equity of 0.00% beat biote's return on equity.
biote has higher revenue and earnings than Theratechnologies. Theratechnologies is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.
21.7% of biote shares are owned by institutional investors. 13.9% of biote shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
biote beats Theratechnologies on 14 of the 18 factors compared between the two stocks.
Get Theratechnologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for THTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Theratechnologies Competitors List
Related Companies and Tools
This page (NASDAQ:THTX) was last updated on 1/15/2025 by MarketBeat.com Staff
